Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Jan 2016 | FROM EXTERNAL EXPERTS

Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways

Xu, P. et al. Toxicology and Applied Pharmacology

Nov 2015 | FROM EXTERNAL EXPERTS

Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders

Zhang, H., Yang, L. Frontiers in Endocrinology

Nov 2014 | FROM EXTERNAL EXPERTS

Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets

Fisher, F.M. et al. Gastroenterology

Nov 2009 | FROM EXTERNAL EXPERTS

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models–association with liver and adipose tissue effects

Xu, J. et al. American Journal of Physiology. Endocrinology and Metabolism

Feb 2007 | FROM EXTERNAL EXPERTS

The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21

Kharitonenkov, A. et al. Endocrinology

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.

View Our Pipeline

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.

View Our Pipeline